MediPoint: In-Vitro Colorectal Cancer Screening Tests - Global Analysis and Market Forecasts

Summary

Colorectal cancer (CRC) is the third most commonly diagnosed cancer, and the second most common cause of mortality amongst cancer patients. Prognosis is directly related to early diagnosis, with survival rates dramatically improved by early diagnosis and treatment. Thanks to the introduction of CRC screening programs, mortality in the developed countries is falling; however incidence continues to rise as a result of diet and increasingly sedentary lifestyles. While historically, colorectal cancer incidence in the developing world is low, in recent years, disease diagnosis rates have dramatically increased, as a result of changing lifestyles, awareness and improved access to medical services. CRC screening can improve survival rates, and reduce the overall cost of patient treatment.

Highlights

Key Questions Answered

- Colorectal cancer can be caused by somatic mutations as well as inherited mutations. These mutations lead to changes in the colon, that can be detected by detection of bleeding. But many of these mutations can be also be detected by genetic and other tests. (Q).How quickly will new gene tests be adopted by the CRC screening market??
- (Q).What are the key differences in CRC screening carried out in different countries, and how will these differences affect adoption of new screening tests?
- Existing CRC screening is based on inexpensive, but inaccurate stool analysis tests, or expensive but accurate endoscopies. The first DNA screening tests are expected to come to market in 2014, from Exact Sciences and EpiGenomics. (Q).Which new DNA-based screening test will win out ?
- In-vitro CRC screening is a fast evolving technological area. (Q).How will change in technology affect sales of existing CRC screening tests?(Q). Who are the new players in CRC screening? (Q).How will patient attitudes affect the In-vitro CRC screening test market?

Scope

- Overview of CRC and CRC screening tests, including epidemiology, etiology, diagnosis, pathology, treatment guidelines, screening test technologies and evolving regulatory structures
- Annualized in-vitro CRC screening test market revenue, annual cost of IVD CRC screening and CRC screening volume data from 2009-2019 and forecast for eight years to 2019
- Key topics covered include strategic competitor assessment, market characterization, identification of unmet needs, reimbursement considerations, and implications for the CRC screening test market

- Pipeline analysis: Emerging CRC screening tests, emerging platform technologies
- Analysis of the current and future market competition in the global CRC screening test market. Insightful review of the key industry drivers, opportunities, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global colorectal cancer screening test market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global colorectal cancer screening test market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track test sales in the global colorectal cancer screening test market from 2009-2019.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table Of Contents

Table of Contents

1 Table of Contents 9
1.1 List of Tables 15
1.2 List of Figures 23
2 Introduction 25
2.1 Catalyst 25
2.2 Related Reports 26
3 Disease Overview 27
3.1 Colorectal Cancer 27
3.2 Anatomy and Physiology 27
3.3 Pathophysiology 29
3.3.1 Histology 29
3.3.2 Genetic Basis 30
3.3.3 Etiology of CRC 31
3.4 Clinical Presentation 33
3.4.1 Symptoms 33
3.4.2 Screening Overview 34
3.4.3 Status of National CRC Screening Programs 35
3.4.4 Diagnosis Overview 42
3.4.5 Staging Colorectal Cancer 47
3.5 Clinical Outcomes 50
3.5.1 Treatment Paradigms 50
3.5.2 Treatment Options Overview 52
3.6 Epidemiology 53
3.6.1 Global and Historical Trends 53
3.7 Epidemiology Forecast (2010-2019) 60
3.7.1 Total Incident Cases of Colorectal Cancer 60
3.8 Economic Impact 62
3.8.1 Individual Costs 62
4 Competitive Assessment 65
4.1 Overview 65
4.2 Fecal Occult Blood Tests 65
4.2.1 Guaiac Fecal Occult Blood Stool Tests 65
4.2.2 Lateral Flow Immuno-Fecal Occult Blood Tests 69
4.2.3 Readers 77
4.2.4 Immuno-FOB Test ELISA 80
4.2.5 Immuno-FOB Agglutination Tests 83
4.3 CRC DNA Screening Tests 93
4.3.1 Panel DNA Tests 93
4.3.2 Methylated Gene Testing 103
4.4 Other Biomarker Tests 111
4.4.1 Overview 111
4.4.2 Tumor M2-PK Stool Test/2-in-1 Quick Test 112
4.4.3 Transferrin Assays 115
5 Unmet Needs 117
5.1 False Negative Results 117
5.2 False Positive Results 119
5.3 Sample Type 121
5.4 Screening Compliance 122
5.5 Alternative to Colonoscopy 125
5.6 Accurate Early Staging of Colorectal Cancer 127
5.7 Screening Test Alternatives 128
5.8 Automation 129
6 Pipeline Products 131
6.1 Overview 131
6.2 Pipeline by Phases in Development 131
6.3 Pipeline Product Profiles 133
6.3.1 BST1 CRC Assay 133
6.3.2 Cologic 134
6.3.3 ColoGuard 136
6.3.4 Colon Cancer BEC Test 140
6.3.5 Colon MarCare Plex 141
6.3.6 Colox 144
6.3.7 CRC Bacterial Signature Assay 146
6.3.8 CRC Breath Test 147
6.3.9 Epi proColon 150
6.3.10 ExiQon MicroRNA Test 156
6.3.11 Gemini CRC Biomarker Assay 159
6.3.12 GenomicTree Methylated DNA Test 160
6.3.13 Measure Fecal Occult Blood Test 162
6.3.14 Metabiomics CRC Test 165
6.3.15 MiR-21 Test 167
6.3.16 Oncolite CR 169
6.3.17 PanC-Dx 171
7 Industry Overview 174
7.1 Colorectal Cancer Screening Test Trends 174
7.1.1 US 174
7.1.2 5EU 181
7.1.3 APAC 187
7.1.4 South America (Brazil) 191
7.2 Market Access 192
7.3 Reimbursement Trends 194
7.3.1 US 194
7.3.2 5EU 196
7.3.3 APAC 200
7.3.4 South America (Brazil) 204
7.4 Regulatory Issues and Recalls 205
7.4.1 US 205
7.4.2 5EU 207
7.4.3 APAC Region Regulation 207
7.4.4 Recalls 208
7.5 Mergers and Acquisitions 209
8 Current and Future Players 210
8.1 Overview 210
8.2 Trends in Corporate Strategy 211
8.3 Company Profiles 212
8.3.1 Abbott Molecular 212
8.3.2 Alere 213
8.3.3 Beckman Coulter 216
8.3.4 Biomarcare Technologies 217
8.3.5 Companion Dx 219
8.3.6 Eiken Chemical 220
8.3.7 Epigenomics 224
8.3.8 Exact Sciences 228
8.3.9 ExiQon 233
8.3.10 Fujirebio (Miraca Holdings) 235
8.3.11 GeneNews 238
8.3.12 GenomicTree 239
8.3.13 Immunostics 241
8.3.14 Kyowa Medex 244
8.3.15 MDx Health (was OncoMethylome) 246
8.3.16 Merck Millipore 248
8.3.17 Metabiomics 251
8.3.18 Mode Diagnostics 253
8.3.19 Oncocyte (Bio Time) 255
8.3.20 Quest Diagnostics 257
8.3.21 R-Biopharm 260
8.3.22 Randox Laboratories 263
8.3.23 ScheBo Biotech 265
8.3.24 SciMarket Technologies 268
8.3.25 Siemens Healthcare 269
8.3.26 Signature Diagnostics 272
8.3.27 Sysmex 274
8.3.28 Veda Lab 276
9 Market Drivers, Opportunities and Barriers 278
9.1 Market Drivers 278
9.1.1 Uptake of Pipeline Biomarker Tests 278
9.1.2 Increasing Incidence of Colorectal Cancer and Improvements in Treatment 280
9.1.3 Patient Reluctance to Colonoscopies in Opportunistic CRC Screening 281
9.1.4 Increasing Volume of FOB Tests in Emerging Markets 282
9.1.5 Increased Pressure on Endoscopy Services 282
9.2 Opportunities 283
9.2.1 Blood Tests 283
9.2.2 Increasing CRC Screening Compliance 283
9.2.3 Integration of CRC Screening Tests with Prognostic Tests and Other Screening Programs 285
9.2.4 Emerging Markets 287
9.3 Market Barriers 288
9.3.1 Cultural and Social Resistance to Stool Tests 288
9.3.2 CRC Screening Awareness and Education 288
9.3.3 Reimbursement 289
9.3.4 Local Requirements 290
9.3.5 Test Complexity 293
9.3.6 Patenting Issues 294
10 Country Outlooks and Forecasts 295
10.1 10 Major Markets Overview 295
10.2 US 300
10.2.1 US Market Analysis 300
10.3 France 303
10.3.1 France Market Analysis 303
10.4 Germany 305
10.4.1 Germany Market Analysis 305
10.5 Italy 307
10.5.1 Italy Market Analysis 307
10.6 Spain 309
10.6.1 Spain Analysis 309
10.7 UK 311
10.7.1 UK Market Analysis 311
10.8 Rest of World 314
10.8.1 Japan Market Analysis 314
10.8.2 Brazil Market Analysis 316
10.8.3 China Market Analysis 318
10.8.4 India Market Analysis 320
11 Appendix 322
11.1 Abbreviations 322
11.2 Bibliography 325
11.3 Research Methodology 379
11.3.1 Coverage 379
11.3.2 Secondary Research 380
11.3.3 Forecasting Methodology 380
11.4 Physicians and Specialists Included in this Study 382
11.5 Primary Research 383
11.6 About the Authors 384
11.6.1 Analysts 384
11.6.2 Global Head of Healthcare 385
11.7 About GlobalData 386
11.8 Disclaimer 386



List of Tables

Table 1: Initial Presenting Symptoms of Colorectal Cancer 33
Table 2: Guideline Organization Recommendations for Non-Invasive Tests 36
Table 3: Colorectal Screening FOB Test Participation in Italy by Age and Sex, 2008 38
Table 4: TNM Classification System to Stage CRC 47
Table 5: Stage Grouping for CRC 48
Table 6: Stage II CRC Sub-Divisions 48
Table 7: Stage III CRC Sub-Divisions 49
Table 8: Stage IV CRC Sub-Divisions 49
Table 9: Dukes System of CRC Classification 50
Table 10: Treatment Guidelines for Colorectal Cancer 51
Table 11: Surgical Options for Colorectal Cancer 52
Table 12: Treatment Alternatives for CRC 53
Table 13: Incident Cases of Colorectal Cancer, Ages ?40 Years, Men and Women, N, 2012-2019 61
Table 14: Costs of CRC Diagnosis, Treatment and Care 62
Table 15: CRC Screening Test Segmentation 65
Table 16: Guaiac Fecal Occult Blood Tests Product Profile 66
Table 17: Guaiac FOB Test SWOT Analysis, 2013 68
Table 18: Immuno-FOB Tests 74
Table 19: Product Profile - Lateral Flow Immunochemical Fecal Occult Blood Tests 76
Table 20: Lateral Flow Immunochemical Fecal Occult Blood Tests SWOT Analysis, 2013 77
Table 21: Product Profile - Veda Lab Easy Reader (Lateral Flow Immunochemical Fecal Occult Blood Tests with Readers) 78
Table 22: Veda Lab Easy Reader (Lateral Flow Immunochemical Fecal Occult Blood Tests with Readers) SWOT Analysis, 2013 79
Table 23: Fecal Occult Blood ELISA Products 80
Table 24: Product Profile - Fecal Occult Blood ELISA 81
Table 25: Immuno-FOB Test ELISA SWOT Analysis, 2013 82
Table 26: Commercially Available Immuno-FOB Agglutination Test Systems 90
Table 27: Product Profile - Immuno-FOB Agglutination Tests 90
Table 28: Immuno-FOB Agglutination Tests SWOT Analysis, 2013 92
Table 29: Key Mutations Associated with CRC 94
Table 30: Key Stages of PCR Gene Test 95
Table 31: Product Profile - PreGen Plus 97
Table 32: PreGen Plus SWOT Analysis, 2013 98
Table 33: Product Profile - K-RAS, B-RAF, PIK3CA Array 99
Table 34: K-RAS, B-RAF, PIK3CA Array SWOT Analysis, 2013 100
Table 35: Product Profile - Colonsentry 101
Table 36: Colonsentry SWOT Analysis, 2013 101
Table 37: Product Profile - Detector C 2.0 102
Table 38: Detector C SWOT Analysis, 2013 103
Table 39: Product Profile - ColoSure 106
Table 40: ColoSure SWOT Analysis, 2013 106
Table 41: Product Profile - MS9 108
Table 42: MS9 SWOT Analysis, 2013 109
Table 43: Septin-9 CRC Screening Marketed Laboratory-Developed Tests 109
Table 44: Product Profile - ColoVantage/Septin-9 110
Table 45: ColoVantage/Septin-9 SWOT Analysis, 2013 111
Table 46: Product Profile - Tumor M2-PK Stool Test/2-in-1 Quick Test 113
Table 47: Tumor M2-PK Stool Test/2-in-1 Quick Test SWOT Analysis, 2013 114
Table 48: Product Profile - Transferrin Assays 115
Table 49: Transferrin Assays SWOT Analysis, 2013 116
Table 50: Major Reasons for Non-compliance with CRC Screening 123
Table 51: Correlation of Fecal Occult Blood Test with Neoplasia 127
Table 52: CRC Screening Tests Pipeline, 2012 132
Table 53: Product Profile - BST1 CRC Assay 133
Table 54: BST1 CRC Assay SWOT Analysis, 2013 134
Table 55: Product Profile - Cologic 135
Table 56: Cologic SWOT Analysis, 2013 136
Table 57: Product Profile - ColoGuard 138
Table 58: ColoGuard SWOT Analysis, 2013 140
Table 59: Product Profile - Colon Cancer BEC Test 141
Table 60: Colon Cancer BEC Test SWOT Analysis, 2013 141
Table 61: Product Profile - Colon MarCare Plex 142
Table 62: Colon MarCare Plex SWOT Analysis, 2013 143
Table 63: Product Profile - Colox 145
Table 64: Colox SWOT Analysis, 2013 146
Table 65: Product Profile - CRC Bacterial Signature Assay 147
Table 66: CRC Bacterial Signature Assay SWOT Analysis, 2013 147
Table 67: Product Profile - CRC Breath Test 149
Table 68: CRC Breath Test SWOT Analysis, 2013 149
Table 69: Product Profile - Epi proColon 152
Table 70: Epi proColon Clinical Trials 152
Table 71: Epi proColon SWOT Analysis, 2013 156
Table 72: ExiQon MicroRNA Sensitivity and Specificity 157
Table 73: Product Profile - ExiQon microRNA Test 157
Table 74: ExiQon microRNA Test SWOT Analysis, 2013 158
Table 75: Product Profile - Gemini CRC Biomarker Assay 159
Table 76: Gemini CRC Biomarker Assay SWOT Analysis, 2013 160
Table 77: Product Profile - GenomicTree Methylated DNA Test 161
Table 78: GenomicTree Methylated DNA Test SWOT Analysis, 2013 162
Table 79: Product Profile - Measure 164
Table 80: Measure SWOT Analysis, 2013 164
Table 81: Product Profile - Metabiomics CRC Test 166
Table 82: Metabiomics CRC Test SWOT Analysis, 2013 167
Table 83: Product Profile - miR-21 Test 168
Table 84: miR-21 Test SWOT Analysis, 2013 168
Table 85: Product Profile - Oncolite-CR 169
Table 86: Oncolite-CR SWOT Analysis, 2013 170
Table 87: Product Profile - PanC-Dx 173
Table 88: PanC-Dx SWOT Analysis, 2013 173
Table 89: Uptake of Colonoscopy, Sigmoidoscopy and FOB Testing in the US 176
Table 90: Projections for Virtual Colonoscopy use for CRC Screening 179
Table 91: Healthcare Systems in the People’s Republic of China 200
Table 92: Healthcare Principles in the People’s Republic of China 202
Table 93: Key Mergers and Acquisitions during 2012-2013 209
Table 94: Company Profile - Abbott Molecular 212
Table 95: Abbott Molecular SWOT Analysis, 2013 213
Table 96: Company Profile - Alere 214
Table 97: Alere SWOT Analysis, 2013 215
Table 98: Company Profile - Beckman Coulter 216
Table 99: Beckman Coulter SWOT Analysis, 2013 217
Table 100: Company Profile - Biomarcare Technologies 218
Table 101: Biomarcare Technologies SWOT Analysis, 2013 218
Table 102: Company Profile - Companion Dx 219
Table 103: Companion Dx SWOT Analysis, 2013 220
Table 104: Company Profile - Eiken Chemical 222
Table 105: Eiken Chemical SWOT Analysis, 2013 223
Table 106: Company Profile - Epigenomics 226
Table 107: Epigenomics SWOT Analysis, 2013 228
Table 108: Company Profile - Exact Sciences 229
Table 109: Exact Sciences SWOT Analysis, 2013 232
Table 110: Company Profile - ExiQon 233
Table 111: ExiQon SWOT Analysis, 2013 234
Table 112: Company Profile - Fujirebio (Miraca Holdings) 235
Table 113: Fujirebio SWOT Analysis, 2013 237
Table 114: Company Profile - GeneNews 238
Table 115: GeneNews SWOT Analysis, 2013 239
Table 116: Company Profile - GenomicTree 240
Table 117: GenomicTree SWOT Analysis, 2013 240
Table 118: Company Profile - Immunostics 241
Table 119: Immunostics SWOT Analysis, 2013 243
Table 120: Company Profile - Kyowa Medex (Kyowa Hakko Kirin Group) 244
Table 121: Kyowa Medex SWOT Analysis, 2013 245
Table 122: Company Profile - MDx Health 246
Table 123: MDx Health SWOT Analysis, 2013 248
Table 124: Company Profile - Merck Millipore 249
Table 125: Merck Millipore SWOT Analysis, 2013 250
Table 126: Company Profile - Metabiomics 251
Table 127: Metabiomics SWOT Analysis, 2013 252
Table 128: Company Profile - Mode Diagnostics 253
Table 129: Mode Diagnostics SWOT Analysis, 2013 254
Table 130: Company Profile - Oncocyte (Bio Time) 255
Table 131: Oncocyte (Bio Time) SWOT Analysis, 2013 256
Table 132: Company Profile - Quest Diagnostics 258
Table 133: Quest Diagnostics SWOT Analysis, 2013 259
Table 134: Company Profile - R-Biopharm 261
Table 135: R-Biopharm SWOT Analysis, 2013 262
Table 136: Company Profile - Randox Laboratories 263
Table 137: Randox Laboratories SWOT Analysis, 2013 264
Table 138: Company Profile - ScheBo Biotech 265
Table 139: Schebo Biotech SWOT Analysis, 2013 267
Table 140: Company Profile - SciMarket Technologies 268
Table 141: SciMarket Technologies SWOT Analysis, 2013 269
Table 142: Company Profile - Siemens Healthcare 270
Table 143: Siemens Healthcare SWOT Analysis, 2013 271
Table 144: Company Profile - Signature Diagnostics 272
Table 145: Signature Diagnostics SWOT Analysis, 2013 273
Table 146: Company Profile - Sysmex 274
Table 147: Sysmex SWOT Analysis, 2013 275
Table 148: Company Profile - Veda Lab 276
Table 149: Veda Lab SWOT Analysis, 2013 277
Table 150: PreGen Plus Compared to Immuno-FOB Test 292
Table 151: Potential Impacts of Restriction of Gene Patents 294
Table 152: Major Events Affecting the Global In-Vitro CRC Screening Test Market 295
Table 153: Sales Forecasts for In-vitro CRC Screening Tests in the 10 Major Markets, 2010-2019 296
Table 154: Forecasts for Numbers of In-vitro CRC Screening Tests, 2010-2019 297
Table 155: Sales Forecasts for In-vitro CRC Screening Tests in the US, 2010-2019 300
Table 156: Sales Forecasts for In-vitro CRC Screening Tests in France, 2010-2019 303
Table 157: Sales Forecasts for In-vitro CRC Screening Tests in Germany, 2010-2019 305
Table 158: Sales Forecasts for In-vitro CRC Screening Tests in Italy, 2010-2019 307
Table 159: Sales Forecasts for In-vitro CRC Screening Tests in Spain, 2010-2019 309
Table 160: Sales Forecasts for In-vitro CRC Screening Tests in the UK, 2010-2019 311
Table 161: Sales Forecasts for In-vitro CRC Screening Tests in Japan, 2010-2019 314
Table 162: Sales Forecasts for In-vitro CRC Screening Tests in Brazil, 2010-2019 316
Table 163: Sales Forecasts for In-vitro CRC Screening Tests in China, 2010-2019 319
Table 164: Sales Forecasts for In-vitro CRC Screening Tests in India, 2010-2019 321

1.2 List of Figures
Figure 1: Colorectal Cancer Staging 28
Figure 2: Global Trends in Colorectal Cancer Incidence, 2010-2019 61
Figure 3: Total Costs of Colorectal Cancer to Society, 2010-2019 64
Figure 4: Example of a Guaiac Fecal Occult Blood Card: Immunostics Hema-Screen 66
Figure 5: Fecal Occult Blood Test Lateral Flow Device Architecture 70
Figure 6: Biohit Colonview (example of immuno-FOB test) 71
Figure 7: Beckman Coulter Hemoccult-ICT (example of immuno-FOB test) 72
Figure 8: Veda Labs Easy Reader Immuno-FOB Test LFD Reader 78
Figure 9: OC-Hemodia Agglutination FOB Test (manually performed) 83
Figure 10: OC-Sensor/Diana FOB Test Sample Cartridge 84
Figure 11: OC-Sensor/Diana FOB Test Instrument 85
Figure 12: Fujirebio HemSp/MagStream HT Magnetic Agglutination Reaction 86
Figure 13: Sentinel Diagnostic Sentifob Instrument 87
Figure 14: Alere CI5 NS-Plus Instrument 88
Figure 15: Orion Diagnostics Quikread FOB Test and Instrument 89
Figure 16: Basic PCR Process 96
Figure 17: MS9 PCR Response Curve 108
Figure 18: Proposed ColoGuard Patient Stool Sample Collection Kit 137
Figure 19: Exact Sciences Automated Sample Processing WorkStation 138
Figure 20: Colox Kit Contents 144
Figure 21: Measure Fecal Occult Blood Test 163
Figure 22: PanC-Dx Multiplex Detection of CRC-specific Biomarker 172
Figure 23: Uptake of FOB Testing in the US by Income, 2002-2006 178
Figure 24: Global Sales Forecast for In-vitro CRC Screening Tests ($m), 2010-2019 296
Figure 25: Global Forecast for Numbers of In-vitro CRC Screening Tests, 2010-2019 297
Figure 26: Global Share of Fecal Occult Blood Tests, by Brand, 2012 299
Figure 27: US Sales Forecast for In-vitro CRC Screening Tests ($m), 2010-2019 300
Figure 28: US Market Segmentation for In-vitro CRC Screening Tests, by Type, 2012 and 2019 301
Figure 29: France Sales Forecast for In-vitro CRC Screening Tests ($m), 2010-2019 303
Figure 30: Germany Sales Forecast for In-vitro CRC Screening Tests ($m), 2010-2019 305
Figure 31: Italy Sales Forecast for In-vitro CRC Screening Tests ($m), 2010-2019 307
Figure 32: Spain Sales Forecast for In-vitro CRC Screening Tests ($m), 2010-2019 309
Figure 33: UK Sales Forecast for In-vitro CRC Screening Tests ($m), 2010-2019 311
Figure 34: Japan Sales Forecast for In-vitro CRC Screening Tests ($m), 2010-2019 314
Figure 35: Brazil Sales Forecast for In-vitro CRC Screening Tests ($m), 2010-2019 316
Figure 36: China Sales Forecast for In-vitro CRC Screening Tests ($m), 2010-2019 318
Figure 37: India Sales Forecast for In-vitro CRC Screening Tests ($m), 2010-2019 320



Companies Mentioned

Abbott Molecular
Alere
Beckman Coulter
Biomarcare Technologies
Companion Dx
Eiken Chemical
Epigenomics
Exact Sciences
ExiQon
Fujirebio (Miraca Holdings)
GeneNews
GenomicTree
Immunostics
Kyowa Medex
MDx Health (was OncoMethylome)
Merck Millipore
Metabiomics
Mode Diagnostics
Oncocyte (Bio Time)
Quest Diagnostics
R-Biopharm
Randox Laboratories
ScheBo Biotech
SciMarket Technologies
Siemens Healthcare
Signature Diagnostics
Sysmex
Veda Lab

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Future Horizons and Growth Strategies in the Global Microbiology Testing Market 2014: Supplier Shares and Country Forecasts

Future Horizons and Growth Strategies in the Global Microbiology Testing Market 2014: Supplier Shares and Country Forecasts

  • $ 21 100
  • Industry report
  • August 2014
  • by Venture Planning Group

Complete report $32,500.  DataPack (test volumes, sales forecasts, supplier shares) $21,100. “2014 Strategies for the Global Microbiology Testing Market” is a new seven-country strategic analysis ...

Analysis of the Global In Vitro Diagnostics Market

Analysis of the Global In Vitro Diagnostics Market

  • $ 10 000
  • Industry report
  • July 2014
  • by Frost & Sullivan

Slowing US and European Markets Demand Alignment with Global Market Needs Despite global economic and industry challenges, in vitro diagnostics (IVD) markets are growing robustly at double the rate of ...

Chemical and Physical Analysis Equipment Markets in Asia to 2018 - Market Size, Trends, and Forecasts

Chemical and Physical Analysis Equipment Markets in Asia to 2018 - Market Size, Trends, and Forecasts

  • $ 7 302
  • Industry report
  • August 2014
  • by Global Research & Data Services

This industry report package offers the most up-to-date market data on the actual market situation, trends, and future outlook for chemical and physical analysis equipment in different Asian countries. ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.